Browsing Tag
ProLectin-M
2 posts
Does host-pathway targeting offer a durable COVID-19 strategy for Bioxytran, Inc.?
Bioxytran, Inc. reports early ProLectin-M data. Explore what host-targeted antivirals mean for COVID-19 strategy and biotech investors.
Bioxytran reports successful clinical trial for ProLectin-M, a broad-spectrum antiviral targeting multiple respiratory viruses
Find out how Bioxytran’s completed randomized trial for ProLectin-M could redefine the antiviral market and reshape biotech investor sentiment.